Loading...
 

Volume 33, Issue 2, June 2022



Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2022;33(2):263-7
Real-Life Outcome of Lupus Nephritis with Current Therapies: Study Protocol of a Multicentre Observational Study
Authors Information

1First Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens, "Laiko" General Hospital, Athens

2Rheumatology Unit, Fourth Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens, “Attikon” University Hospital, Athens

3Department of Rheumatology, “Asklepieion” General Hospital, Athens, Greece

4Rheumatology Unit, Sismanogleio General Hospital, Athens, Greece

5Department of Rheumatology, “G. Gennimatas” General Hospital, Athens, Greece

6First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece

7Fourth Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

8Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens, Athens, Greece

9Rheumatology and Clinical Immunology, University of Crete Medical School and University Hospital of Iraklio, Iraklio, Greece

P Sidiropoulos, D Boumpas, G Bertsias, M Tektonidou, A Fanouriakis

Abstract

Lupus nephritis (LN) affects a significant proportion of patients with systemic lupus erythematosus (SLE) and is characterised by increased morbidity and mortality. The updated joint EULAR/European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) recommendations for the management of LN have set as target of therapy the optimisation (preservation or improvement) of kidney function, accompanied by a reduction in proteinuria of at least 25% by 3 months, 50% by 6 months, and below 500–700 mg/g by 12 months (complete clinical response). It is currently unknown what proportion of Greek patients with LN reach these proposed targets with the current available treatments. At the same time, recent successful phase 3 trials have led to the approval of both belimumab and voclosporin for the treatment of patients with LN and have steered discussions as to whether the “induction-maintenance” paradigm should be substituted by an early combination treatment for all patients. To inform future therapeutic decisions and facilitate the positioning of these new drugs in the therapeutic algorithm of LN, the current study protocol aims to map the unmet needs in the treatment of LN in Greece, by quantifying the proportion of patients who attain the recommended treatment targets in everyday clinical practice.



Cite this article as: Pappa M, Kosmetatou M, Elezoglou A, Boki K, Konstantopoulou P, Papagoras C, Garyfallos A, Vassilopoulos D, Sidiropoulos P, Sfikakis P, Boumpas D, Bertsias G, Tektonidou M, Fanouriakis A. Real-Life Outcome of Lupus Nephritis with Current Therapies: Study Protocol of a Multicentre Observational Study. Mediterr J Rheumatol 2022;33(2):263-7.

Article Submitted: 2 Feb 2022; Article Accepted: 15 Feb 2022; Available Online: 30 Jun 2022.

https://doi.org/10.31138/mjr.33.2.263

This work is licensed under a Creative Commons Attribution 4.0 International License.

©Pappa M, Kosmetatou M, Elezoglou A, Boki K, Konstantopoulou P, Papagoras C, Garyfallos A, Vassilopoulos D, Sidiropoulos P, Sfikakis P, Boumpas D, Bertsias G, Tektonidou M, Fanouriakis A.